言語:
通貨:

1 000 000 顧客は私達の大きいサービスおよび良質プロダクトを選びました

  • 最大80%オフ

    大幅割引とセールを実施

  • 迅速な海外発送

    注文した商品がすばやく届く

  • 処方箋不要

    規制なく医薬品を購入しよう

  • 返金保証

    30日返金保証

Doctor
お客様のカートに商品はありません。

認証を受けた薬局

M認可を受けた証明書は100種以上

  • fda
  • fda
  • pgeu gpue
  • mipa
  • cipar
  • mastercard
  • visa
  • mcafee

Banners

Movfor

購入_Movfor_オンライン
  • Movfor 200mg

    パッケージ 1錠あたり 特別価格
    200 キャップ 無料お急ぎ配送 $5.49 $1466 -26% たったの $1097
    160 キャップ 無料お急ぎ配送 $5.60 $1173 -24% たったの $896
    120 キャップ 無料お急ぎ配送 $5.79 $880 -21% たったの $695
    80 キャップ 無料お急ぎ配送 $6.18 $587 -16% たったの $494
    40 キャップ 無料通常配送 $7.33 たったの $293

Product Description

Common use
Easily distributed oral antivirals are urgently needed to treat coronavirus disease-2019 (COVID-19), prevent progression to severe illness, and block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the results of a Phase 2a trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19.

Dosage and direction

Eligible participants included outpatients with confirmed SARS-CoV-2 infection and symptom onset within 7 days. Participants were randomized 1:1 to 200 mg molnupiravir or placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo, twice-daily for 5 days.
Antiviral activity was assessed as time to undetectable levels of viral RNA by reverse transcriptase polymerase chain reaction and time to elimination of infectious virus isolation from nasopharyngeal swabs.

Results

Among 202 treated participants, virus isolation was significantly lower in participants receiving 800 mg molnupiravir (1.9%) versus placebo (16.7%) at Day 3 (p = 0.02). At Day 5, virus was not isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Time to viral RNA clearance was decreased and a greater proportion overall achieved clearance in participants administered 800 mg molnupiravir versus placebo (p = 0.01). Molnupiravir was generally well tolerated, with similar numbers of adverse events across all groups.

Conclusions

Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile.

あなたも気に入るかもしれません:

購読する 特別オファーとニュース
購読する

testimonials

    5 stars

矢藤 夏希 「今までネットショップにこれほど満足したことはないです。商品はすぐ届くし、サービスも使いやすかったです。」

お客様の声